The Efficacy of Botulinum Toxin in OVERACTIVE Bladder

NCT03888001 | Unknown DMC

• 1 other identifier: Botox in overactive bladder
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the efficacy of botulinum toxin injection in overactive bladder.

Conditions

Overactive Bladder

Outcome Measures

Primary Outcomes (1)

• Efficacy of Botulinum Toxin injection in overactive Bladder

  By using of quistionaire mainly arabic validation of urogenital distress inventory ( UDI-6 quistionaire) throug appling quistions to patients that compare between symptoms before and after botox injection...

  1 year

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with either sex and above age of 6 years with diagnosis of idiopathic or neurogenic overactive bladder diagnosed clinically and urodynamically admitted to Assiut university hospital. Paitent with neurogenic lowcompliance or detrusor overactivity affecting bladder function

You may qualify if:

• patients with spastic neurogenic bladder due to upper motor neuron lesion as (spinal cord lesions ,multiple sclerosis ,strokes,parkinsonism...........).
• patients with idiopathic overactive bladder
• patients with spastic neurogenic bladder diagnosed clinically and urodynamically.

You may not qualify if:

• patients with diabetes mellitus.
• Atonic bladder.
• Children below 6 years.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Ahmed Farahat

Asyut, Egypt

RECRUITING

Related Publications (1)

• 1. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-66. 2. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8 Suppl 5:21-9. 3. Tanagho EA, McAninch JW, editors. Smith's General Urology. 17th ed. New York: The McGraw-Hill Companies, Inc., 2008,438-53. 4. Sellers DJ, McKay N. Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol2007;17:223-30. 5-Aoki, K.R. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 2001; 248: 3-10

  BACKGROUND

MeSH Terms

Conditions

Urinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• AHMED FARAHAT, MASTER

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

AHMED FARAHAT, MASTER

CONTACT

01069569946; ahmedfarahat363@yahoo.com

mahmoud FARAHAT, MASTER

CONTACT

01069569946; ahmedfarahat363@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principle invistigator

Study Record Dates

• First Submitted: March 18, 2019
• First Posted: March 25, 2019
• Study Start: January 1, 2018
• Primary Completion: April 1, 2019
• Study Completion: March 1, 2020
• Last Updated: March 25, 2019

Record last verified: 2019-03

Locations

EG (1)